2015-2019 Japanese Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets: Country Forecasts, Emerging Technologies, Competitive Strategies

September 2015 | 410 pages | ID: 232E69CA79FEN
Venture Planning Group

Abstracts

Complete report $2,450. DataPack (test volumes, sales forecasts, supplier shares) $1,450. The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget.

This new study from VPGMarketResearchcontains 410 pages, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years.

Report Highlights

• Market shares of leading suppliers
• Business and technological trends in major markets
• Five-year test volume and sales forecasts
• Market shares of leading competitors
• Feature comparison of major analyzers
• Strategic profiles of leading market players and start-up firms developing innovative products
• Specific product and business opportunities for instrument and consumable suppliers.

Rationale

Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Japan Market Overview

• Laboratories performing DNA sequencing and molecular diagnostic testingby country and market segment.
• Five-year test volume and sales projections.

Market Segmentation Analysis

• Five-year test volume and sales projections:
• Infectious Diseases - Forensic Testing
• Cancer - Paternity Testing/HLA Typing
• Genetic Diseases - Others
• A comprehensive analysis of the sequencing market by laboratory segment.
• Detailed market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and major suppliers.

Product/Technology Review

• Comparison of the major molecular diagnosticanalyzers.
• Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over target/signal amplification methods.
• Worldwide listings of companies, universities and research centers developing new molecular diagnostictechnologies and products.

Competitive Assessments

Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

• Abbott
• Affymetrix
• Agilent Technologies
• Applied Gene Technologies
• Arca Biopharma
• Beckman Coulter/Danaher
• Becton Dickinson
• Biokit
• BioMerieux
• Bio-Rad
• Biotest
• Cepheid
• CellMark Forensics Lab/Corp
• Decode Genetics
• Diadexus
• Eiken
• Elitech Group
• Enzo
• Exact Sciences
• Fujirebio
• Grifols
• Hologic/Gen-Probe
• Illumina
• Kreatech/Leica
• Li-Cor Biosciences
• Monogram Biosciences
• Myriad Genetics
• Ortho-Clinical Diagnostics
• Perkin Elmer/Caliper
• Proteome Sciences
• Qiagen
• Roche
• Scienion
• Sequenom
• Shimadzu
• Siemens
• Sierra Molecular
• Takara Bio
• Tecan Group
• Thermo Fisher

Comprehensive listings of companies developing and marketing molecular diagnostic products, by test and application.

Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.
• Business planning issues and concerns.

Contains 410 pages

Contents

INSTRUMENTATION REVIEW

Introduction
Benk Hemolab
Benk TRT Thrombotimer
Bio/Data MCA
Bio/Data MCA
Bio/Data PAP4C D/4D/4C
Cardiovascular Diagnostics COAG
Diagnostica Stago STA Compact
Diagnostica Stago STAR
Diagnostica Stago Star 4/8
Helena Laboratories Cascade
Helena Laboratories Cascade M
Helena Laboratories PACKS-
Helena THOR
Instrumentation Laboratory ACL 100 and 1000 series
Instrumentation Laboratory ACL6000
Instrumentation Laboratory ACL7000
Instrumentation Laboratory ACL9000
Instrumentation Laboratory Electra 1000C
Instrumentation Laboratory Electra 1400C
Instrumentation Laboratory Electra 1600/C
Instrumentation Laboratory Electra 1800C
Instrumentation Laboratory Futura
ITC Hemochron 8000
Roche Diagnostics CoaguChek
Siemens BCS
Siemens BCT
Siemens BF II/Fibrintimer Series
Sysmex CA-
Sysmex CA-
Sysmex CA1500
Sysmex CA5000/CA1000
Sysmex CA6000
Sysmex CA7000
Teco Coatron II/Jr./AccuStasis 5000
Trinity Biotech Amax CS190
Trinity Biotech Amax CS400
Trinity Biotech CoagAMate Max
Trinity Biotech KC 40, 4A, 1A Series
Trinity Biotech MDA
Trinity Biotech CoagAMate MTX
Trinity Biotech CoagAMate RA4
Trinity Biotech CoagAMate XC/Plus
Trinity Biotech CoagAMate XM

COMPETITIVE ASSESSMENTS

Abbott
ADI/American Diagnostica
Alere/Biosite/Inverness
AxisShield
Beckman Coulter/Danaher
Becton Dickinson
Bio/Data Corporation
ChronoLog
Corgenix Medical
Diagnostica Stago/Trinity Biotech
Grifols
Helena Laboratories
Hyphen BioMed
Instrumentation Laboratory
ITC/Nexus Dx
Roche
Siemens
Sienco
Sysmex
Thermo Fisher
ZyCare/Alere